Multicancer Early Detection Screening Does Not Reduce Overall Late-Stage Cancer Diagnosis
A large-scale randomized trial in England found that annual blood-based multicancer screening did not significantly reduce the incidence of late-stage cancers. The study followed over 140,000 participants to evaluate the clinical utility of the Galleri test.
Why it matters
These findings challenge the current efficacy of early detection blood tests in reducing late-stage cancer diagnoses, impacting future screening guidelines and public health policy.
The results of the randomized NHS-Galleri trial reported by Sasieni et al in The New England Journal of Medicine showed that annual screening with a blood-based multicancer early detection test added to usual care did not result in a significantly lower incidence rate of stage III or IV cancers across 12 prespecified cancer types after three screening rounds.
The ongoing prospective trial, conducted in England, evaluated the clinical utility of the Galleri multicancer early detection blood test when added to usual care. The test analyzes methylation patterns in cell-free DNA to detect a cancer signal and predict its tissue or organ of origin.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in